Wedbush lowered shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from an outperform rating to a neutral rating in a research note released on Wednesday, MarketBeat reports. They currently have $12.00 price objective on the stock, down from their previous price objective of $38.00. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2023 earnings at […]